Gary Michael Ginsberg

Summary

Country: Israel

Publications

  1. doi Generalizability of cost-utility analyses across countries and settings
    Gary M Ginsberg
    Medical Technology Assessment Sector, Ministry of Health, Yirmiahu St 39, Jerusalem 944724, Israel Electronic address
    Best Pract Res Clin Gastroenterol 27:845-52. 2013
  2. pmc Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis
    Gary M Ginsberg
    Medical Technology Assessment Sector, Ministry of Health, Jerusalem, Israel
    Isr J Health Policy Res 2:6. 2013
  3. pmc Economic effects of interventions to reduce obesity in Israel
    Gary M Ginsberg
    Medical Technology Assessment Sector, Ministry of Health, Ben Tabai 2, Jerusalem, Israel
    Isr J Health Policy Res 1:17. 2012
  4. pmc Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-Saharan Africa and South East Asia: mathematical modelling study
    Gary M Ginsberg
    Department of Medical Technology Assessment, Ministry of Health, Ben Tbai 2, San Simone, Jerusalem, Israel
    BMJ 344:e614. 2012
  5. pmc Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models
    Mark Jit
    Modelling and Economics Unit, Health Protection Agency, London, UK
    BMC Med 9:54. 2011
  6. ncbi Cost-utility analysis of vaccination against HPV in Israel
    Gary Michael Ginsberg
    Medical Technology Assessment Sector, Ministry of Health, Ben Tbai 2, San Simone, Jerusalem, Israel
    Vaccine 25:6677-91. 2007
  7. doi Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis
    Gary Michael Ginsberg
    World Health Organization, Health Systems Financing Department, Costs, Effectiveness, Expenditure and Priority Setting Unit, Geneva, Switzerland
    Vaccine 27:6060-79. 2009
  8. doi Issues in estimating smoking attributable mortality in Israel
    Gary M Ginsberg
    Department of Technology Assessment, Israel Ministry of Health, Jerusalem, Israel
    Eur J Public Health 20:113-9. 2010
  9. ncbi The burden of uncomplicated cases of chickenpox in Israel
    Eli Somekh
    The Pediatric Infectious Diseases and Immunology Unit, E Wolfson Medical Center, Holon, 58100, Israel
    J Infect 45:233-6. 2002

Collaborators

Detail Information

Publications9

  1. doi Generalizability of cost-utility analyses across countries and settings
    Gary M Ginsberg
    Medical Technology Assessment Sector, Ministry of Health, Yirmiahu St 39, Jerusalem 944724, Israel Electronic address
    Best Pract Res Clin Gastroenterol 27:845-52. 2013
    ..However, if time constraints are pressing then first-order estimates of results could be presented after adjustments for the major drivers of the CUR, such as incidence rates, intervention costs and averted treatment costs...
  2. pmc Should Israel screen all mothers-to-be to prevent early-onset of neonatal group B streptococcal disease? A cost-utility analysis
    Gary M Ginsberg
    Medical Technology Assessment Sector, Ministry of Health, Jerusalem, Israel
    Isr J Health Policy Res 2:6. 2013
    ..This paper presents a cost-utility analysis of implementing an alternative strategy, which would expand the current protocol to one aiming to screen all pregnant women at 35-37 weeks gestation based on taking a vaginal culture for GBS...
  3. pmc Economic effects of interventions to reduce obesity in Israel
    Gary M Ginsberg
    Medical Technology Assessment Sector, Ministry of Health, Ben Tabai 2, Jerusalem, Israel
    Isr J Health Policy Res 1:17. 2012
    ..abstract:..
  4. pmc Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-Saharan Africa and South East Asia: mathematical modelling study
    Gary M Ginsberg
    Department of Medical Technology Assessment, Ministry of Health, Ben Tbai 2, San Simone, Jerusalem, Israel
    BMJ 344:e614. 2012
    ..To determine the costs and health effects of interventions to combat breast, cervical, and colorectal cancers in order to guide resource allocation decisions in developing countries...
  5. pmc Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models
    Mark Jit
    Modelling and Economics Unit, Health Protection Agency, London, UK
    BMC Med 9:54. 2011
    ..To provide information about the feasibility of using such models in a developing country setting, we evaluated models of HPV vaccination in terms of their capacity, requirements, limitations and comparability...
  6. ncbi Cost-utility analysis of vaccination against HPV in Israel
    Gary Michael Ginsberg
    Medical Technology Assessment Sector, Ministry of Health, Ben Tbai 2, San Simone, Jerusalem, Israel
    Vaccine 25:6677-91. 2007
    ..85, $50.42 and $27.20, respectively. Attempts should be made to raise compliancy with PAP smears from the current opportunistic 12.2-20.0% per annum either before and/or after the vaccination is introduced...
  7. doi Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis
    Gary Michael Ginsberg
    World Health Organization, Health Systems Financing Department, Costs, Effectiveness, Expenditure and Priority Setting Unit, Geneva, Switzerland
    Vaccine 27:6060-79. 2009
    ..Treatment should also be increased where coverage is low...
  8. doi Issues in estimating smoking attributable mortality in Israel
    Gary M Ginsberg
    Department of Technology Assessment, Israel Ministry of Health, Jerusalem, Israel
    Eur J Public Health 20:113-9. 2010
    ....
  9. ncbi The burden of uncomplicated cases of chickenpox in Israel
    Eli Somekh
    The Pediatric Infectious Diseases and Immunology Unit, E Wolfson Medical Center, Holon, 58100, Israel
    J Infect 45:233-6. 2002
    ..The aim of this study was to assess the direct medical burden and work loss associated with uncomplicated chickenpox in Israel...